Xeris Biopharma Holdings, Inc.
XERS- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001867096
In the last 90 days, Xeris Biopharma Holdings, Inc. insiders filed 0 open-market purchases and 10 sales; 242 institutions reported holding it in 13F filings for Q2 2026, worth $857.1M in total; no superinvestor holds it.
Q2 2023 vs. Q1 2023
How the institutions holding Xeris Biopharma Holdings, Inc. changed between Q1 2023 and Q2 2023.
All holders in Q2 2023All holders in Q1 2023
| Measure | Q1 2023 | Q2 2023 | Change |
|---|---|---|---|
| Holders | 92 | 105 | +13 |
| Shares | 49.5M | 56.0M | +6.54M (+13.2%) |
| Value | $80.6M | $146.7M | +$66.1M (+82.0%) |
New holders (21)
Institutions that held Xeris Biopharma Holdings, Inc. at the end of Q2 2023 but not at the end of Q1 2023.
Sold out (8)
Institutions that held Xeris Biopharma Holdings, Inc. at the end of Q1 2023 and filed for Q2 2023 without it.
| Institution | Shares, Q1 2023 | Value, Q1 2023 |
|---|---|---|
| Rubric Capital Management LP | 426,267 | $694.8K |
| XTX Topco Ltd | 233,385 | $380.4K |
| Yakira Capital Management, Inc. | 90,076 | $146.8K |
| SG Americas Securities, LLC | 40,947 | $67.0K |
| Kavar Capital Partners Group, LLC | 17,000 | $27.7K |
| Gladstone Institutional Advisory LLC | 10,500 | $17.1K |
| TSFG, LLC | 5,488 | $9.00K |
| TCI Wealth Advisors, Inc. | 200 | $326 |